On September 3, 2019 Pfizer Inc. reported invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Chief Financial Officer and Executive Vice President, Global Supply and Business Operations, at the Morgan Stanley 17th Annual Global Healthcare Conference on Monday, September 9, 2019 at 3:40 p.m. Eastern Daylight Time (Press release, Pfizer, SEP 3, 2019, View Source [SID1234539200]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and pre-registering for the webcast will be available at www.pfizer.com/investors beginning today.

Visitors will be able to listen to an archived copy of the webcast at www.pfizer.com/investors.

On September 3, 2019 Aurora Cannabis Inc. ("Aurora" or the "Company") (NYSE | TSX: ACB), reported that it has scheduled its conference call to discuss the results for its fourth quarter and fiscal year ended June 30, 2019 on Thursday, September 12th, 2019 at 9:00 a.m. Eastern Time (Press release, Aurora BioPharma, SEP 3, 2019, View Source [SID1234539217]). Terry Booth, Chief Executive Officer, Glen Ibbott, Chief Financial Officer, Cam Battley, Chief Corporate Officer, and Michael Singer, Executive Chairman, will host the call and a question and answer period. The Company will report its financial results for the fourth quarter and fiscal year end after the close of markets on Wednesday, September 11th, 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CONFERENCE CALL DETAILS

DATE:

Thursday, September 12th, 2019

TIME:

9:00 a.m. Eastern Time | 7:00 a.m. Mountain Time

WEBCAST:

https://bit.ly/34gYCj5

REPLAY:

(416) 849-0833 or (855) 859-2056
Available until 12:00 midnight Eastern Time Thursday, September 19, 2019

REFERENCE NUMBER:

6084057

About Aurora

Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 625,000 kg per annum and sales and operations in 25 countries across five continents, Aurora is one of the world’s largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high-quality consistent product. Designed to be replicable and scalable globally, our production facilities are designed to produce cannabis at significant scale, with high quality, industry-leading yields, and low-per gram production costs. Each of Aurora’s facilities is built to meet European Union Good Manufacturing Practices ("EU GMP") standards. Certification has been granted to Aurora’s first production facility in Mountain View County, the MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland. All Aurora facilities are designed and built to the EU GMP standard.

In addition to the Company’s rapid organic growth and strong execution on strategic M&A, which to date includes 17 wholly owned subsidiary companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs, Whistler, Chemi Pharmaceutical, and Hempco – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc. (TSX: CLIQ), High Tide Inc. (CSE: HITI), EnWave Corporation (TSXV: ENW), Capcium Inc. (private), Evio Beauty Group (private), and Wagner Dimas (private).

Aurora’s Common Shares trade on the TSX and NYSE under the symbol "ACB", and is a constituent of the S&P/TSX Composite Index.

For more information about Aurora, please visit our investor website, investor.auroramj.com

On September 3, 2019 Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, reported the appointment of Shakti Narayan, J.D., Ph.D., as its Chief Executive Officer and a member of the Board of Directors (Press release, accent therapeutics, SEP 3, 2019, View Source [SID1234539233]). Dr. Narayan brings a strong record of experience in life sciences, having held various leadership roles which led to transformational achievements within both the biotechnology and pharmaceutical industries.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Accent is defining a new and practical paradigm for addressing RNA pathobiology by targeting the proteins that control many aspects of RNA biology, unlocking the potential of RNA biology and providing new hope for patients," said Robert A. Copeland, Ph.D., President and Chief Scientific Officer of Accent. "We are delighted to welcome Shakti to Accent. He brings a wealth of biopharma experience and leadership as we advance our leading position in the field of RNA modification."

"Accent has made incredible progress developing a pipeline of targeted therapies in this novel area of biology and is well-positioned to accelerate its impact in the field," said Dr. Narayan. "I’m thrilled to be joining the exceptional team at Accent as we work to better the course of cancer treatment for patients."

Dr. Narayan was most recently Chief Business Officer of Tango Therapeutics, where he was responsible for business development, finance and various operational functions. During his tenure at Tango, he led a $1.7B transformational partnership with Gilead Sciences. Prior to Tango, Dr. Narayan was Vice President, Head of Transactions at Johnson & Johnson Innovation, where he helped build J&J’s Innovation Centers model, led oncology business development efforts and led a team of dealmakers who drove transactions for multiple J&J businesses. Prior to his time at J&J, Dr. Narayan led business development as part of the management team at Nodality, a VC-backed personalized medicine biotechnology company, where he developed the company’s partnering strategy, led and closed multiple strategic collaborations and held various operational roles.

Dr. Narayan’s career began in business development at Genentech and as a life sciences transactional attorney at Wilson Sonsini Goodrich & Rosati. Dr. Narayan earned his Bachelor of Arts in biology from Grinnell College, obtained his Ph.D. in cellular and molecular biology at the University of Wisconsin Madison and the Salk Institute and was a post-doctoral scientist at Stanford University. His legal studies were completed at the University of California Berkeley School of Law, where he earned a J.D.

On September 3, 2019 Bristol-Myers Squibb Company (NYSE: BMY) reported that it will take part in a fireside chat at the Morgan Stanley Conference on Monday, September 9, 2019, in New York (Press release, Bristol-Myers Squibb, SEP 3, 2019, View Source [SID1234539182]). Giovanni Caforio, M.D., chairman and chief executive officer will answer questions at 4:15 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to a live webcast of the session at View Source Materials related to the presentation will be available at the same website at the start of the live webcast. An archived edition of the session will be available later that day.

On September 3, 2019 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, reported that an overview of the company’s business strategy and development-stage programs will be given at two upcoming conferences being held in New York on September 10th and September 11th (Press release, Spectrum Pharmaceuticals, SEP 3, 2019, View Source [SID1234539201]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Rodman & Renshaw 21st Annual Global Investment Conference, Sponsored by H.C. Wainwright
When: Tuesday, September 10, 2019 at 9:10 AM ET
Morgan Stanley 17th Annual Global Healthcare Conference
When: Wednesday, September 11, 2019 at 1:35 PM ET
The presentations will be webcast live and may be accessed by visiting Spectrum’s website at View Source